Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer Reviews Published on 2021-02-202022-10-05 Journal: Nature Reviews Clinical Oncology [Category] 바이오마커, [키워드] age Anderson Cancer Center baseline Cancer CAR Care cells children chimeric antigen receptor clinical trials Committee criteria Critical care Deterioration European facilitate Health hematopoietic immune Immune-checkpoint inhibitors immunotherapies Immunotherapy Inclusion indicated management Marrow network Organ failure organ function pathology Patients with cancer Program receiving recommendation recommendations regulatory agency researchers Society Sponsor Support therapeutic response Therapies toxicities Toxicity transplantation unique working [DOI] 10.1038/s41571-021-00474-4 [Article Type] Reviews
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case reportCOVID-19 감염 후 재발 및 불응성 다발성 골수종 환자에서 항BCMA CAR T 투여: 증례 보고Case Reports Published on 2021-02-192022-09-12 Journal: Journal of Medical Case Reports [Category] MERS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered administration Antigen antigen receptor antiviral antibodies antiviral antibody benefit Cancer patients CAR CAR T cell Case report Cell Cell therapy Chemotherapy chimeric antigen receptor clinical recovery clinical study Complete coronavirus coronavirus disease COVID-19 COVID-19 diagnosis COVID-19-related complications criteria CRS Cytokine release syndrome decision detectable dose Enrollment exacerbate global pandemic group Host immune immune response Immunosuppression infections initial male maturation Multiple myeloma Myeloma novel Novel coronavirus novel coronavirus disease pandemic Patient potential risk proceed receiving Registered risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus severe acute respiratory syndrome Coronavirus susceptible T cell the patient the SARS-CoV-2 virus therapy treated Treatment viral infection working [DOI] 10.1186/s13256-020-02598-0 PMC 바로가기 [Article Type] Case Reports
COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new IssueCOVID-19 관련 사이토카인 폭풍 증후군 및 진단 원칙: 오래된 문제와 새로운 문제Review Published on 2021-02-182022-09-10 Journal: Emerging Microbes & Infections [Category] SARS, 유전자 메커니즘, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Antigen Autoimmune disease Autoimmune diseases autologous benefit Bone marrow CAR-T Characteristics chimeric chimeric antigen receptor claimed clinical experience Clinical sign Clinical signs clinician coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CRS CSS cytokine cytokine release Cytokine release syndrome Cytokine storm Cytokine storm syndrome Cytokines Deterioration diagnosed diagnoses diagnosing Diagnosis diagnostic Diagnostic Criteria disease early stage early stages Evolution familial/primary hemophagocytic lymphohistiocytosis hemophagocyte hemophagocytic lymphohistiocytosis hemophagocytic syndrome HLH include issue less limitation Macrophage macrophage activation macrophage activation syndrome malignancy mechanisms non-specific paper Pathogenesis Patient Research respiratory SARS-CoV-2 secondary hemophagocytic lymphohistiocytosis sensitivity severe acute respiratory syndrome Coronavirus sHLH Signs and symptoms Symptoms T-cell T-cell receptor therapy [DOI] 10.1080/22221751.2021.1884503 PMC 바로가기 [Article Type] Review
Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study중증 COVID-19에 대한 토실리주맙의 초기 임상 결과: 2개 센터 후향적 연구Multicenter Study Published on 2021-02-012022-09-11 Journal: International journal of antimicrobial agents [Category] MERS, 진단, 치료제, [키워드] (coronavirus disease 2019 Analysis antigen receptor blood cell CAR chimeric antigen receptor Clinical improvement Clinical outcome Cohort conducted coronavirus disease Coronavirus disease 2019 COVID-19 Critically ill Critically ill patient critically ill patients CRS cytokine Cytokine release syndrome Day Drug administration effective Efficacy elevated evaluated had no hospital IL-6 IL-6 inhibitor Immunomodulatory agents inflammatory markers inhibitor interleukin-6 Lactate lactate dehydrogenase Lower New oxygen Patient patients patients treated primary endpoint respiratory status retrospective cohort study Retrospective study SARS-CoV-2 secondary to severe COVID-19 significantly supplemental oxygen T-cell therapy Tocilizumab tocilizumab administration treated treating COVID-19 Treatment Univariate analysis USA White blood cell with COVID-19 worsened [DOI] 10.1016/j.ijantimicag.2020.106265 PMC 바로가기 [Article Type] Multicenter Study
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms말초 염증 및 혈액-뇌 장벽 파괴: 효과 및 메커니즘Review Published on 2020-12-302022-09-12 Journal: CNS Neuroscience & Therapeutics [Category] MERS, 진단, [키워드] blood vessel blood–brain barrier Brain Cell cellular and molecular Central nervous system chimeric antigen receptor circulation CNS Complication Cytokine storm demonstrated Diseases disrupt Effect exacerbated Factor homeostasis immune cells Inflammation Inflammatory diseases inflammatory factors inflammatory mediator mechanism molecular mechanism normal organ Pathways peripheral peripheral circulation physiological regulate Research resulting SARS‐CoV‐2 infection therapy [DOI] 10.1111/cns.13569 PMC 바로가기 [Article Type] Review
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 PneumoniaSARS-CoV-2 폐렴 치료를 위한 토실리주맙의 자비로운 사용Article Published on 2020-12-152022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 신약개발, 진단, 치료기술, [키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse events anti-IL-6R antigen receptor appear approved benefit C-reactive protein C-reactive protein (CRP chimeric antigen receptor clinical and laboratory parameters clinical trials compassionate use coronavirus COVID-19 CRP cytokine Cytokine storm death Decline declines dose drug Drug administration Efficacy event examined Follow-up food Food and Drug Administration hospitalized patient hospitalized patients IL-6 IL-6R Inflammation interleukin interleukin 6 Intubated laboratory parameter Laboratory parameters mechanical ventilation morbidity morbidity and mortality Mortality occurred offer outcomes oxygen Oxygen requirements oxygen saturation oxygen saturations oxygen support pathogenic Patient patients patients with SARS-CoV-2 Placebo placebo-controlled Pneumonia predominant Preliminary data profiles proof Randomized rationale reducing required respiratory respiratory distress Respiratory distress syndrome SARS-CoV-2 SARS-CoV-2 pneumonia SARS-CoV2 Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus Significant reduction significant reductions single-center study supported T-cell temperature therapy Tocilizumab Treatment vasopressor requirement vasopressor requirements vasopressor support [DOI] 10.1093/cid/ciaa812 PMC 바로가기 [Article Type] Article
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation조혈모세포 이식 환자에서 코로나19의 유리한 결과Clinical Trial Published on 2020-12-012022-09-12 Journal: The Journal of Clinical Investigation [Category] MERS, SARS, 임상, 진단, [키워드] active malignancy Allogeneic Antibody Response antiviral response autologous CAR Cell cell transplantation cellular center Characteristics chimeric antigen receptor clinical Clinical outcome clinical variable composite endpoint COVID-19 Critical death diagnosed disease event identify immune investigated IQR lymphocyte Lymphocyte subsets median time Memorial nasopharyngeal swabs neutropenia number of comorbidity outcome overall survival Oxygen requirement Patient patients patients with COVID-19 patients with SARS-CoV-2 Population quantitative real-time PCR recipient recipients reduction SARS-CoV-2 SARS-CoV-2 antibody severity significantly stem cell Stem cell transplantation subset T cell T cells therapy transplantation variable with COVID-19 [DOI] 10.1172/JCI141777 PMC 바로가기 [Article Type] Clinical Trial
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast CancerReview Published on 2020-11-262023-08-30 Journal: Cancers [Category] E형 간염, [키워드] Cancer metabolism cancer nanomedicine chimeric antigen receptor combination therapy Immune checkpoint inhibitor Immunotherapy triple-negative breast cancer tumor antigens tumor microenvironment [DOI] 10.3390/cancers12123529 PMC 바로가기 [Article Type] Review
Tocilizumab therapy in 5 solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2SARS-CoV-2로 인한 초기 ARDS가 있는 고형 및 복합 조직 이식 수혜자 5명에 대한 토실리주맙 요법Case Reports Published on 2020-11-012022-09-12 Journal: American journal of transplantation : official jou [Category] SARS, 진단, [키워드] acute respiratory distress acute respiratory syndrome ARDS Bacterial infection characterized chimeric antigen receptor Clinical course Clinical management clinical research/practice clinical utility condition coronavirus coronavirus disease Course COVID-19 CRP cytokine Cytokine release syndrome data-driven described dysregulated immune response elevated Guidance high mortality IL-6 IL-6 receptor Infection infection and infectious agents - viral infectious agent Infectious disease Inflammatory response involved occurred off-label off-label drug use. organ outcome Oxygenation Protein Randomized recipient reductions in reported Respiratory mechanics response SARS-CoV-2 solid organ transplant Support syndrome T-cell therapeutic agent therapy tissue Tocilizumab tocilizumab administration Trial variety vasopressors ventilator [DOI] 10.1111/ajt.16080 PMC 바로가기 [Article Type] Case Reports
Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic LeukemiaReview Published on 2020-10-162024-09-02 Journal: International Journal of Molecular Sciences [Category] 대상포진, [키워드] chimeric antigen receptor Immunotherapy leukemia-initiating cells monoclonal antibodies Relapse T-cell acute lymphoblastic leukemia [DOI] 10.3390/ijms21207685 PMC 바로가기 [Article Type] Review